

Drug Monograph

Drug Name: **Elyxyb™ (celecoxib) solution**
 Drug Class: **Central Nervous System: Analgesics, NSAIDS**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Elyxyb is available as a 120 mg/4.8 mL oral solution of celecoxib.

Manufacturer: Distributed by: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540.

Indications: Elyxyb is indicated for the acute treatment of migraine with or without aura in adults.

Costs: \$135 per 4.8 mL. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation:

| | |
|--|---|
| <input type="checkbox"/> Clinical Edit | <input type="checkbox"/> PA Required |
| <input type="checkbox"/> Open Access | <input checked="" type="checkbox"/> PDL |

Type of PA Criteria:

| | |
|--|---|
| <input type="checkbox"/> Appropriate Indications | <input checked="" type="checkbox"/> Non-Preferred |
| <input type="checkbox"/> No PA Required | <input type="checkbox"/> Preferred |

Prepared by: April Ash, PharmD
 Date: December 30, 2021